Strategies and challenges for the next generation of therapeutic antibodies

  title={Strategies and challenges for the next generation of therapeutic antibodies},
  author={Alain Beck and Thierry Wurch and Christian Bailly and Nathalie Corvaia},
  journal={Nature Reviews Immunology},
Antibodies and related products are the fastest growing class of therapeutic agents. By analysing the regulatory approvals of IgG-based biotherapeutic agents in the past 10 years, we can gain insights into the successful strategies used by pharmaceutical companies so far to bring innovative drugs to the market. Many challenges will have to be faced in the next decade to bring more efficient and affordable antibody-based drugs to the clinic. Here, we discuss strategies to select the best… 

Strategies for Development of Next Generation Antibody-Based Therapeutics

Recent approaches employed for development of next generation antibody-based therapeutics are discussed, with the potential to displace their first-generation rivals based on improved therapeutic activity, safety, and increased dosing convenience.

Developments and Challenges for mAb-Based Therapeutics

The continuous increase in the number of approved monoclonal antibody (mAb)-based therapy suggests that mAbs, and their derivatives, will continue to be the focus of the biotherapeutics industry for years to come, but there are still challenges to be overcome.

Strategies and challenges for the next generation of antibody–drug conjugates

Strategies to select the best target antigens as well as suitable cytotoxic drugs; the design of optimized linkers; the discovery of bioorthogonal conjugation chemistries; and toxicity issues are discussed.

Antibody therapy of cancer

This Review outlines the fundamental strategies that are required to develop antibody therapies for cancer patients through iterative approaches to target and antibody selection, extending from preclinical studies to human trials.

Therapeutic targets and recent advances in protein immunotoxins.

Clinical pharmacology of bispecific antibody constructs

This knowledgebase on the clinical behavior of bispecific therapeutic proteins is poised to rapidly evolve over the next few years with many development programs having entered the clinical development stage.

Antigen generation and display in therapeutic antibody drug discovery – a neglected but critical player

This review summarizes the most important aspects of antigen generation and display, enabling logical decision making to give rise to potent high‐affinity antibodies.



Considerations for the development of therapeutic monoclonal antibodies.

Glycosylation as a strategy to improve antibody-based therapeutics

Current knowledge of methods and avenues for their exploitation in the clinic are summarized, which allow the production of rMAbs bearing pre-selected oligosaccharides — glycoforms — to provide maximum efficacy for a given disease indication.

Therapeutic antibodies for autoimmunity and inflammation

How key insights obtained from the development of therapeutic antibodies complemented by newer antibody engineering technologies are delivering a second generation of therapeutic antibody with promise for greater clinical efficacy and safety is reviewed.

Bispecific antibodies for cancer therapy: the light at the end of the tunnel?

This review describes the most recent advances and clinical study results in the field of bispecific antibodies, a new class of molecules that might outshine conventional mAbs as cancer immunotherapeutics in a near future.

Engineered protein scaffolds as next-generation antibody therapeutics.

Antibodies to watch in 2010

This overview of the 26 mAbs provides a brief description of the background and the on-going Phase 3 studies of each mAb, and will serve as a baseline against which future progress can be measured.

Monoclonal antibodies: versatile platforms for cancer immunotherapy

This work states that antibodies exhibit various immunomodulatory properties and, by directly activating or inhibiting molecules of the immune system, antibodies can promote the induction of antitumour immune responses and form the basis for new cancer treatment strategies.

When binding is enough: nonactivating antibody formats.

How to systematically evaluate immunogenicity of therapeutic proteins - regulatory considerations.